About collegium pharmaceutical inc - COLL
Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.
COLL At a Glance
Collegium Pharmaceutical, Inc.
100 Technology Center Drive
Stoughton, Massachusetts 02072
| Phone | 1-781-713-3699 | Revenue | 780.57M | |
| Industry | Pharmaceuticals: Major | Net Income | 62.87M | |
| Sector | Health Technology | 2025 Sales Growth | 23.615% | |
| Fiscal Year-end | 12 / 2026 | Employees | 423 | |
| View SEC Filings |
COLL Valuation
| P/E Current | 20.531 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 26.687 |
| Price to Sales Ratio | 2.355 |
| Price to Book Ratio | 4.866 |
| Price to Cash Flow Ratio | 5.58 |
| Enterprise Value to EBITDA | 5.732 |
| Enterprise Value to Sales | 3.034 |
| Total Debt to Enterprise Value | 0.395 |
COLL Efficiency
| Revenue/Employee | 1,845,312.057 |
| Income Per Employee | 148,628.842 |
| Receivables Turnover | 3.694 |
| Total Asset Turnover | 0.466 |
COLL Liquidity
| Current Ratio | 1.571 |
| Quick Ratio | 1.478 |
| Cash Ratio | 0.924 |
COLL Profitability
| Gross Margin | 59.349 |
| Operating Margin | 23.968 |
| Pretax Margin | 11.866 |
| Net Margin | 8.054 |
| Return on Assets | 3.754 |
| Return on Equity | 23.701 |
| Return on Total Capital | 5.078 |
| Return on Invested Capital | 5.349 |
COLL Capital Structure
| Total Debt to Total Equity | 310.409 |
| Total Debt to Total Capital | 75.634 |
| Total Debt to Total Assets | 55.542 |
| Long-Term Debt to Equity | 300.33 |
| Long-Term Debt to Total Capital | 73.178 |